Gain Therapeutics prices $9.4M public offering and concurrent private placement of common stock and warrants

On November 21, 2023, Gain Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Newbridge Securities Corporation, as the underwriter named therein (the “ Underwriter ”), relating to the offering, issuance and sale of an aggregate of (i) 2,213,044 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”) and (ii) warrants to purchase 1,106,522 shares of Common Stock (the “ Warrants ” and the shares of Common Stock underlying the Warrants, the “ Warrant Shares ”) for aggregate gross proceeds of $4.4 million (the “ Offering ”).

On November 21, 2023, in a private placement (the “ Concurrent Private Offering ”) to be completed concurrently with the completion of the Offering, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (“ Private Purchaser ”) whereby the Company will issue an aggregate of (i) 744,026 shares of Common Stock (the “ Private Shares ”), (ii) pre-funded warrants (the “ Pre-Funded Warrants ”) exercisable for an aggregate of up to 1,756,062 shares of Common Stock and (iii) warrants (the “ Private Warrants ”) to purchase up to an aggregate of 2,500,088 shares of the Company’s common stock (“ Private Warrant Shares ”) for aggregate gross proceeds of $5.0 million.